Author

Y. Perera

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Immunology· 2 Bioengineering· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Assay:proteomics· 7 Organism:human· 5 Research Focus:differential expression· 4 Research Focus:cell type annotation· 3 Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

G. V. Perez· 5 shared S. E. Perea· 5 shared A. C. Ramon· 4 shared M. Rosales· 4 shared Y. Ramos· 4 shared A. Rodriguez-Ulloa· 3 shared J. R. Wisniewski· 3 shared L. J. Gonzalez· 3 shared

Activity by Year

2020-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

G. V. Perez

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

On Casein Kinase-2 (CK2) deregulation in NSCLC: an enzyme subunit-centered approach

G. V. Perez, L. Chen, D. Chenyi, Y. Ying, Z. Qiang, Z. Zhiwei, Y. Ke, S. E. Perea, Y. Perera

This study investigates CK2 subunit deregulation in NSCLC using multiomics data and IHC, finding that CSNK2A1 and CSNK2B upregulation correlates with poor prognosis and tumor progression.

bioRxiv · Aug 4, 2023 · PreprintCancer Biology

Gene Expression Profiling Unveils the Temporal Dynamics of CIGB-300-Regulated Transcriptome in AML Cells

D. Vazquez-Blomquist, A. C. Ramon, M. Rosales, G. V. Perez, A. Rosales, D. Palenzuela, Y. Perera, S. E. Perea

This study uses microarray profiling to analyze the time-dependent gene expression changes in AML cell lines treated with CIGB-300, identifying modulated genes and pathways involved in apoptosis, cell cycle, and inflammation.

bioRxiv · Mar 6, 2023 · PreprintCancer Biology

CIGB-300 peptide targets the CK2 phospho-acceptor domain on Human Papillomavirus E7 and disrupts the Retinoblastoma (RB) complex in cervical cancer cells

A. d. l. C. Ramon, O. Basukala, P. Massimi, M. Thomas, Y. Perera, L. Banks, S. Perea

This study investigates how CIGB-300 peptide targets HPV-16 E7, disrupts CK2-mediated phosphorylation, and affects the E7-pRB interaction in cervical cancer cells.

bioRxiv · Jun 23, 2022Cancer Biology

The Nucleocapsid Protein Of SARS-CoV-2, Combined With ODN-39M, Is A Potential Component For An Intranasal Bivalent Pancorona Vaccine

Y. Lobaina, R. Chen, E. Suzarte, P. Ai, V. Huerta, A. Musacchio, R. Silva, C. Tan, A. Martin, L. Lazo, G. Guillen, K. Yang, Y. Perera, L. Hermida

This paper evaluates a bivalent intranasal vaccine candidate combining SARS-CoV-2 N protein and ODN-39M, showing cross-reactive immunity against SARS-CoV-1 and enhanced Th1 response when combined with RBD.

bioRxiv · Jun 2, 2022 · PreprintImmunology

Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection

A. C. Ramon, G. V. Perez, E. Caballero, M. Rosales, D. Aguilar, D. M. Vazquez-Blomquist, Y. Ramos, A. Rodriguez, V. Falcon, M. P. Rodriguez, Y. Ke, Y. Perera, S. E. Perea

This study shows that CIGB-325, an anti-CK2 peptide, inhibits bovine coronavirus infection by reducing viral protein accumulation and cytopathic effects.

bioRxiv · Jun 8, 2021Pharmacology & Toxicology

Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300

M. Rosales, G. V. Perez, A. C. Ramon, Y. Cruz, A. Rodriguez-Ulloa, V. Besada, Y. Ramos, D. Vazquez-Blomquist, E. Caballero, D. Aguilar, L. J. Gonzalez, K. Zettl, J. R. Wisniewski, Y. Ke, Y. Perera, S. E. Perea

This study investigates the anti-proliferative and proapoptotic effects of the CK2 inhibitor CIGB-300 on AML cells and identifies its molecular targets.

bioRxiv · May 19, 2021Cancer Biology

Gel Electrophoresis/Electroelution Sorting Fractionator combined with Filter Aided Sample preparation (FASP) for deep proteomic analysis.

Y. Ramos, A. Almeida, J. Carpio, A. Rodriguez-Ulloa, Y. Perera, L. J. Gonzalez, J. R. Wisniewski, V. Besada

The paper introduces a new device for protein fractionation and demonstrates its effectiveness in increasing protein identification in proteomic analysis.

bioRxiv · Apr 16, 2021Bioengineering

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945

M. Rosales, A. Rodriguez-Ulloa, V. Besada, A. C. Ramon, G. V. Perez, Y. Ramos, O. Guirola, L. J. Gonzalez, K. Zettl, J. R. Wisniewski, Y. Perera, S. E. Perea

This study examines the phosphoproteomic changes in AML cell lines treated with CX-4945, identifying key biological processes and pathways affected by CK2 inhibition.

bioRxiv · Jan 4, 2021Cancer Biology

Development and validation of an assay for detection of Japanese Encephalitis virus specific antibody responses

P. D. Pushpakumara, C. Jeewandara, L. Gomes, Y. Perera, A. Wijewickrama, G. N. Malavige, C. Goonesekara

This paper develops an ELISA to detect JEV-specific antibodies that do not cross-react with DENV and finds that JEV seropositivity is associated with severe dengue.

bioRxiv · Aug 21, 2020Immunology